Ramon Arens

Immunotherapy for persistent viral infections and associated disease.

Differential B7-CD28 costimulatory requirements for stable and inflationary mouse cytomegalovirus-specific memory CD8 T cell populations.

Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.

Rational design of vaccines: learning from immune evasion mechanisms of persistent viruses and tumors.

Polyfunctional CD4+ T cell responses to immunodominant epitopes correlate with disease activity of virulent Salmonella.

Vaccine-induced effector-memory CD8+ T cell responses predict therapeutic efficacy against tumors.

Predicting the efficacy of cancer vaccines by evaluating T-cell responses.

CD27-CD70 costimulation controls T cell immunity during acute and persistent cytomegalovirus infection.

Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer.

Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.

Lysine acetyltransferase PCAF is a key regulator of arteriogenesis.

The distinct role of T cell costimulation in antiviral immunity.

Nodular inflammatory foci are sites of T cell priming and control of murine cytomegalovirus infection in the neonatal lung.

Viral inoculum dose impacts memory T-cell inflation.

Local immunomodulation for cancer therapy: Providing treatment where needed.

New advances in CMV and immunosenescence.

Enhanced cross-presentation and improved CD8+ T cell responses after mannosylation of synthetic long peptides in mice.

T Cell factor 1 represses CD8+ effector T cell formation and function.

The activation of the adaptive immune system: cross-talk between antigen-presenting cells, T cells and B cells.

Vaccine-induced tumor necrosis factor-producing T cells synergize with cisplatin to promote tumor cell death.

CD55 deposited on synovial collagen fibers protects from immune complex-mediated arthritis.

Enhanced CD8 T cell responses through GITR-mediated costimulation resolve chronic viral infection.

5(th) International Workshop on CMV and Immunosenescence - A shadow of cytomegalovirus infection on immunological memory.

Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression.

New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer.

Cytomegalovirus- and Epstein-Barr Virus-Induced T-Cell Expansions in Young Children Do Not Impair Naive T-cell Populations or Vaccination Responses: The Generation R Study.

Therapeutic cancer vaccines.

The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansion.

Abatacept decreases disease activity in a absence of CD4(+) T cells in a collagen-induced arthritis model.

The Quantity of Autocrine IL-2 Governs the Expansion Potential of CD8+ T Cells.

Murine cytomegalovirus (CMV) infection via the intranasal route offers a robust model of immunity upon mucosal CMV infection.

In Vivo Killing Capacity of Cytotoxic T Cells Is Limited and Involves Dynamic Interactions and T Cell Cooperativity.

Viral Persistence Induces Antibody Inflation without Altering Antibody Avidity.

Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.

Tumor Eradication by Cisplatin Is Sustained by CD80/86-Mediated Costimulation of CD8+ T Cells.

The Breadth of Synthetic Long Peptide Vaccine-Induced CD8+ T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection.

Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination.

The importance of correctly timing cancer immunotherapy.

Wnt Signaling as Master Regulator of T-Lymphocyte Responses: Implications for Transplant Therapy.

Peptide Processing Is Critical for T-Cell Memory Inflation and May Be Optimized to Improve Immune Protection by CMV-Based Vaccine Vectors.

Enforced OX40 Stimulation Empowers Booster Vaccines to Induce Effective CD4 and CD8 T Cell Responses against Mouse Cytomegalovirus Infection.

Inhibition of 14q32 microRNA miR-495 reduces lesion formation, intimal hyperplasia and plasma cholesterol levels in experimental restenosis.

CD4 T Cell and NK Cell Interplay Key to Regression of MHC Class I Tumors upon TLR7/8 Agonist Therapy.

CMV immune evasion and manipulation of the immune system with aging.

Human plasmacytoid dendritic cells acquire phagocytic capacity by TLR9 ligation in the presence of soluble factors produced by renal epithelial cells.

Exhaustion and Inflation at Antipodes of T Cell Responses to Chronic Virus Infection.

The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose.

Features of Effective T Cell-Inducing Vaccines against Chronic Viral Infections.

A flexible MHC class I multimer loading system for large-scale detection of antigen-specific T cells.

Impact of congenital cytomegalovirus infection on transcriptomes from archived dried blood spots in relation to long-term clinical outcome.

FcγRI expression on macrophages is required for antibody-mediated tumor protection by cytomegalovirus-based vaccines.

OX40 Stimulation Enhances Protective Immune Responses Induced After Vaccination With Attenuated Malaria Parasites.

Cytomegalovirus infection and progressive differentiation of effector-memory T cells.

: A workflow for visual and quantitative analysis of flow and mass cytometry data to discover immune signatures and correlations.

.

Demarcated thresholds of tumor-specific CD8 T cells elicited by MCMV-based vaccine vectors provide robust correlates of protection.

T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword.

Peripheral and systemic antigens elicit an expandable pool of resident memory CD8 T cells in the bone marrow.

The hallmarks of CMV-specific CD8 T-cell differentiation.

CD8+ T Cells Protect During Vein Graft Disease Development.

PD-L1 blockade engages tumor-infiltrating lymphocytes to co-express targetable activating and inhibitory receptors.

A poly-neoantigen DNA vaccine synergizes with PD-1 blockade to induce T cell-mediated tumor control.